Melanoma Dispatch
2.6K views | +2 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

MK3475 Induced High Rates of Durable Responses in Advanced Melanoma

MK3475 Induced High Rates of Durable Responses in Advanced Melanoma | Melanoma Dispatch | Scoop.it

"A majority of patients with advanced melanoma who had and had not received previous ipilimumab demonstrated durable responses with the PD-1 targeted antibody MK-3475, according to study results presented at the ASCO Annual Meeting.


“ 'This is the largest phase 1 clinical trial ever conducted in this disease, and together with a lung cancer cohort, this is the largest phase 1 trial ever done in oncology,' study investigator Antoni Ribas, MD, PhD, professor of medicine at the David Geffen School of Medicine at the University of California in Los Angeles, said during a press conference. 'These are early data, but they tell us we are on to something really important.' ”


Editor's note: The cancer drug MK-3475 is an immunotherapy, meaning that it boosts a patient's own immune system to fight cancer. This story describes a clinical trial that tested MK-3475 on volunteer patients with advanced melanoma, and found good results for a majority of the patients. Some of the patients had previously been treated with the drug ipilimumab (Yervoy) and some had not; both kinds of patients benefited from MK-3475 in the trial.

Cancer Commons's insight:

Healio  |  Jun 3, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

PD-1 Blocker Shrinks Melanomas in Early Trial

PD-1 Blocker Shrinks Melanomas in Early Trial | Melanoma Dispatch | Scoop.it

Results of an ongoing phase I clinical trial reinforce the promise of an experimental immunotherapy drug against melanoma. The drug, lambrolizumab, blocks a protein called PD-1, which lets cancer cells evade the immune system. In the new study, researchers gave lambrolizumab to 135 people with melanomas that had spread. Tumors shrank in more than half of those who got the highest dose of lambrolizumab (10 mg/kg every 2 wk), and disappeared completely in 12 people. Moreover, tumors still had not grown again more than a year later. Side effects were generally mild. This trial is currently accepting new participants.

Cancer Commons's insight:

The New England Journal of Medicine│Jul 11, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

FDA Speeds Review of Experimental Immunotherapy for Melanoma

The U.S. Food and Drug Administration (FDA) has fast-tracked the review of lambrolizumab, an immunotherapy drug for melanoma being developed by the pharmaceutical company Merck. Lambrolizumab, also called MK-3475, disrupts a protein called PD-1 that allows tumor cells to evade the immune system. The expedited review was granted on the strength of promising early results from a clinical trial: tumors shrank in half of those treated with lambrolizumab (43 out of 85), and disappeared in another 9%. Encouragingly, tumors also shrank in 11 of the 27 patients (41%) who had previously been treated with ipilimumab, another immunotherapy drug that is currently used to treat melanomas that have spread. Clinical trials with lambrolizumab are also underway for other types of cancer, including non-small cell lung cancer (NSCLC).

Cancer Commons's insight:

RX Times │ Apr 24, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Biomarker Identifies Melanoma Patients Who May Respond to Immunotherapy MK-3475

Biomarker Identifies Melanoma Patients Who May Respond to Immunotherapy MK-3475 | Melanoma Dispatch | Scoop.it

"Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented here at the AACR Annual Meeting 2014, April 5-9.


"When the protein PD-L1, which is present on some melanoma tumors, binds to PD-1, a protein present on T cells, "brakes" are applied on these T cells, preventing them from attacking the cancer cells. The immunotherapy MK-3475 blocks PD-1, releasing the brakes on T cells and enabling them to attack the cancer cells."


Editor's note: This story is about a drug called MK-3475 (aka lambrolizumab), which boosts a patient's own immune system to fight cancer. It has shown promising results in clinical trials. Learn more about MK-3475 in this blog post.

Cancer Commons's insight:

Medical Xpress  |  Apr 7, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Fast-Tracked Immunotherapy Drug Still Promising for Melanoma

Encouraging results are in from the first clinical trial of lambrolizumab, an experimental immunotherapy drug that was granted a speedy review by the U.S. Food and Drug Administration in April. Formerly known as MK-3475, lambrolizumab blocks a protein (PD-1) that lets tumor cells evade the immune system. The researchers treated 135 people with melanomas that had spread, giving some a lower dose and others a higher dose of the new drug. The study showed that tumors shrank in 38% of all those treated and in 52% of those treated with the higher dose. While the side effects were generally mild, 13% of those treated had more serious reactions, such as thyroid problems or lung or kidney inflammation. This clinical trial is currently recruiting new participants.

Cancer Commons's insight:

New England Journal of Medicine│Jun 2, 2013

more...
No comment yet.